BACKGROUND: Major depression occurs in 4.4% to 20% of the general population. Studies
suggest that major depression is accompanied by immune dysregulation and activation of …

Objective To conduct a systematic review and meta‐analysis of studies that measured cytokine
and chemokine levels in individuals with major depressive disorder ( MDD ) compared to …

Objectives To quantify and compare potential benefits (subjective reports of sleep variables)
and risks (adverse events and morning-after psychomotor impairment) of short term …

Background: Cholinesterase inhibitors (ChEIs) are the only drugs marketed for the treatment
of Alzheimer's disease. Despite numerous randomized controlled trials, the efficacy and …

Mounting evidence suggests that aberrations in immune-inflammatory pathways contribute
to the pathophysiology of major depressive disorder (MDD), and individuals with MDD may …

Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling.
This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented …

Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing
substantial distress for both people with dementia and their caregivers, and contributing to early …

Objectives Increasing evidence suggests that inflammation is involved in Alzheimer’s disease
(AD) pathology. This study quantitatively summarised the data on peripheral inflammatory …

Background Mild Behavioral Impairment (MBI) is a construct that describes the emergence
at≥ 50 years of age of sustained and impactful neuropsychiatric symptoms (NPS), as a …

Background The mechanisms through which physical activity supports healthy brain
function remain to be elucidated. One hypothesis suggests that increased brain-derived …